Header

UZH-Logo

Maintenance Infos

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy


Krieg, Carsten; Nowicka, Malgorzata; Guglietta, Silvia; Schindler, Sabrina; Hartmann, Felix J; Weber, Lukas M; Dummer, Reinhard; Robinson, Mark D; Levesque, Mitchell P; Becher, Burkhard (2018). High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 24(2):144-153.

Abstract

Immune-checkpoint blockade has revolutionized cancer therapy. In particular, inhibition of programmed cell death protein 1 (PD-1) has been found to be effective for the treatment of metastatic melanoma and other cancers. Despite a dramatic increase in progression-free survival, a large proportion of patients do not show durable responses. Therefore, predictive biomarkers of a clinical response are urgently needed. Here we used high-dimensional single-cell mass cytometry and a bioinformatics pipeline for the in-depth characterization of the immune cell subsets in the peripheral blood of patients with stage IV melanoma before and after 12 weeks of anti-PD-1 immunotherapy. During therapy, we observed a clear response to immunotherapy in the T cell compartment. However, before commencing therapy, a strong predictor of progression-free and overall survival in response to anti-PD-1 immunotherapy was the frequency of CD14+CD16−HLA-DRhi monocytes. We confirmed this by conventional flow cytometry in an independent, blinded validation cohort, and we propose that the frequency of monocytes in PBMCs may serve in clinical decision support.

Abstract

Immune-checkpoint blockade has revolutionized cancer therapy. In particular, inhibition of programmed cell death protein 1 (PD-1) has been found to be effective for the treatment of metastatic melanoma and other cancers. Despite a dramatic increase in progression-free survival, a large proportion of patients do not show durable responses. Therefore, predictive biomarkers of a clinical response are urgently needed. Here we used high-dimensional single-cell mass cytometry and a bioinformatics pipeline for the in-depth characterization of the immune cell subsets in the peripheral blood of patients with stage IV melanoma before and after 12 weeks of anti-PD-1 immunotherapy. During therapy, we observed a clear response to immunotherapy in the T cell compartment. However, before commencing therapy, a strong predictor of progression-free and overall survival in response to anti-PD-1 immunotherapy was the frequency of CD14+CD16−HLA-DRhi monocytes. We confirmed this by conventional flow cytometry in an independent, blinded validation cohort, and we propose that the frequency of monocytes in PBMCs may serve in clinical decision support.

Statistics

Citations

Dimensions.ai Metrics
94 citations in Web of Science®
85 citations in Scopus®
18 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

16 downloads since deposited on 26 Jan 2018
16 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
04 Faculty of Medicine > Institute of Experimental Immunology
08 Research Priority Programs > Translational Cancer Research
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:2018
Deposited On:26 Jan 2018 11:32
Last Modified:08 Jan 2019 17:12
Publisher:Nature Publishing Group
ISSN:1078-8956
Additional Information:European Union (EU), Horizon 2020
OA Status:Green
Publisher DOI:https://doi.org/10.1038/nm.4466
PubMed ID:29309059
Project Information:
  • : FunderH2020
  • : Grant ID641458
  • : Project TitleMELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival

Download

Download PDF  'High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 3MB
View at publisher